TRUST
Multi-modal effects of thyroid hormone replacement for untreated older adults with subclinical hypothyroidism; a randomised placebo-controlled trial
| Coordinatore | UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.trustthyroidtrial.com/ |
| Totale costo | 7˙764˙598 € |
| EC contributo | 5˙963˙787 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-11-01 - 2016-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
UK (GLASGOW) | coordinator | 2˙329˙422.80 |
| 2 |
UNIVERSITAET BERN
Organization address
address: Hochschulstrasse 4 contact info |
CH (BERN) | participant | 1˙316˙579.60 |
| 3 |
UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK
Organization address
address: Western Road contact info |
IE (CORK) | participant | 1˙111˙161.60 |
| 4 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 1˙106˙622.00 |
| 5 |
LEYDEN ACADEMY ON VITALITY AND AGEING
Organization address
address: RIJNSBURGERWEG POORTGB K 10 contact info |
NL (LEIDEN) | participant | 100˙001.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Subclinical hypothyroidism (SCH) is a common condition (8-18%) among European older men and women. Although by definition SCH comprises biochemically mild thyroid hormone deficiency without overt symptoms, it is a likely contributor to multiple problems in older age. Thyroid hormone has multiple pleiotropic effects on numerous physiological systems, including the vascular tree, heart, skeletal muscle and brain. Therefore, thyroxine substitution to overcome thyroid hormone deficiency has the potential to give multi-system benefits to older people with SCH. Small studies have reported reduced atherosclerosis and improved cardiac function with thyroxine replacement, but no large clinical trials have been performed. Therefore the available evidence is limited, leading to major variations in guidelines and clinical practice, with uncertainty regarding the indications for screening and treatment. We propose a multicentre randomised placebo-controlled trial to assess the impact of thyroxine replacement in 3,000 older adults with persisting SCH (excluding those in whom it is a temporary phenomenon who are less likely to benefit). We will include older men and women with a wide age range and of varying health status. Outcomes include cardiovascular events, health-related quality of life, muscle strength and executive cognitive function over 3-years of follow-up. We have the support of patient advocacy groups and a consortium with the wide range of expertise and experience required to conduct large-scale multicentre clinical trials. The proposal fits with the call, exploring the multi-system and quality-of-life benefits to older people of a tailored approach to management of SCH. This clinical trial should definitively clarify whether thyroxine treatment for SCH provides benefits that are relevant for patients. This trial will provide strong evidence with the potential to improve clinical practice, reduce healthcare costs and promote healthy ageing of European older adults.'